Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase Ib-II study of APG-115 alone or with APG-2575 in relapsed or refractory neuroblastoma or solid tumors
CTR20230193Phase 2Active
- Sponsor
- Suzhou Yasheng Pharmaceutical
- Start
- Mar 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of alrizomadlin, lisaftoclax in neuroblastoma, Nonhematologic neoplasms, sponsored by Suzhou Yasheng Pharmaceutical. Started Mar 2023; status: active.
02
Drugs
alrizomadlinlisaftoclax
03
Conditions
neuroblastomaNonhematologic neoplasms
Beyond the preview
Go deeper on CTR20230193.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20230193.